ANI Pharmaceuticals
ANIP
190 hedge funds and large institutions have $544M invested in ANI Pharmaceuticals in 2019 Q1 according to their latest regulatory filings, with 37 funds opening new positions, 58 increasing their positions, 54 reducing their positions, and 17 closing their positions.
118% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 17
110% more call options, than puts
Call options by funds: $6.86M | Put options by funds: $3.26M
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
70% more capital invested
Capital invested by funds: $319M → $544M (+$225M)
12% more funds holding
Funds holding: 170 → 190 (+20)
5.31% more ownership
Funds ownership: 59.76% → 65.07% (+5.3%)
7% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 54
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Nomura Holdings
Tokyo,
Japan
|
+$12.3M |
| 2 |
HRCM
Hawk Ridge Capital Management
Los Angeles,
California
|
+$7.27M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$6.28M |
| 4 |
GACM
Global Alpha Capital Management
Montreal,
Quebec, Canada
|
+$5.68M |
| 5 |
ICOM
Investment Counselors of Maryland
Baltimore,
Maryland
|
+$4.09M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$3.39M |
| 2 |
Citigroup
New York
|
-$2.21M |
| 3 |
Bank of New York Mellon
New York
|
-$1.75M |
| 4 |
WAM
Weiss Asset Management
Boston,
Massachusetts
|
-$1.66M |
| 5 |
WAM
Wellesley Asset Management
Portsmouth,
New Hampshire
|
-$1.28M |
ANIP Hedge Fund Activity: Q1 2019 in Review
190 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in ANI Pharmaceuticals (ANIP) for Q1 2019, worth a combined $544M — up 70% from $319M a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new ANIP positions and 17 closed out — a net gain of 20 holders — while 58 added to existing stakes and 54 trimmed.
The largest buyer was Nomura Holdings, adding an estimated $12.3M. The largest seller was JP Morgan Chase, cutting an estimated $3.39M.
- 190 institutional investors held ANI Pharmaceuticals (ANIP) as of Q1 2019, up from 170 in Q4 2018.
- Funds reported $544M of ANI Pharmaceuticals stock for Q1 2019, up 70% quarter-over-quarter.
- 37 funds opened new ANI Pharmaceuticals positions in Q1 2019 and 17 closed out, a net change of +20 holders.
- The largest ANI Pharmaceuticals buyer in Q1 2019 was Nomura Holdings, an estimated $12.3M added.
- The largest ANI Pharmaceuticals seller in Q1 2019 was JP Morgan Chase, an estimated $3.39M sold.
Based on aggregated 13F filings for Q1 2019.